Q1 EPS Estimates for Prime Medicine Raised by HC Wainwright

Prime Medicine, Inc. (NYSE:PRME) – Analysts at HC Wainwright raised their Q1 2026 earnings estimates for Prime Medicine in a research note issued to investors on Wednesday, March 4th. HC Wainwright analyst A. He now forecasts that the company will earn ($0.28) per share for the quarter, up from their previous estimate of ($0.33). The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine’s Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($1.19) EPS, FY2028 earnings at ($1.01) EPS, FY2029 earnings at ($0.82) EPS and FY2030 earnings at ($0.62) EPS.

PRME has been the topic of several other reports. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Prime Medicine in a report on Monday, November 10th. Citigroup cut their price objective on Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Chardan Capital decreased their price objective on Prime Medicine from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Finally, Lifesci Capital began coverage on shares of Prime Medicine in a report on Tuesday, December 23rd. They set an “outperform” rating and a $6.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Prime Medicine has a consensus rating of “Moderate Buy” and a consensus price target of $7.21.

Prime Medicine Stock Down 4.6%

Shares of PRME stock opened at $3.93 on Friday. Prime Medicine has a 12-month low of $1.11 and a 12-month high of $6.94. The firm has a fifty day moving average of $3.82 and a 200-day moving average of $4.17. The firm has a market capitalization of $709.41 million, a price-to-earnings ratio of -1.92 and a beta of 2.56.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PRME. Farallon Capital Management LLC lifted its stake in Prime Medicine by 533.3% in the 3rd quarter. Farallon Capital Management LLC now owns 4,750,000 shares of the company’s stock valued at $26,315,000 after acquiring an additional 4,000,000 shares in the last quarter. State Street Corp raised its holdings in shares of Prime Medicine by 293.0% in the fourth quarter. State Street Corp now owns 5,095,510 shares of the company’s stock valued at $17,681,000 after purchasing an additional 3,798,884 shares during the last quarter. ARK Investment Management LLC boosted its holdings in Prime Medicine by 135.8% during the third quarter. ARK Investment Management LLC now owns 5,477,851 shares of the company’s stock worth $30,347,000 after purchasing an additional 3,155,182 shares during the last quarter. Balyasny Asset Management L.P. grew its position in Prime Medicine by 6,426.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 3,124,362 shares of the company’s stock valued at $10,842,000 after purchasing an additional 3,076,489 shares in the last quarter. Finally, Woodline Partners LP acquired a new stake in Prime Medicine in the 3rd quarter valued at $16,634,000. 70.37% of the stock is currently owned by institutional investors.

Key Prime Medicine News

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Lifesci Capital reiterated an “Outperform” rating with a $6.00 price target and modeled FY2026 EPS of ($0.90), notably less negative than the current consensus of ($1.68), suggesting expected improvement in the company’s loss profile. Lifesci Capital estimates and rating
• Positive Sentiment: An analyst-consensus summary showed Prime Medicine has an average analyst rating of “Moderate Buy,” which can attract buying interest from funds and retail investors. Prime Medicine receives average “Moderate Buy”
• Neutral Sentiment: Lifesci published granular quarterly EPS forecasts (Q4 2025 and each quarter of 2026 at ~$ (0.23) per quarter) that give investors a clearer guidance baseline for modeling cash needs and runway but don’t change near-term operations. Detailed quarterly EPS estimates
• Negative Sentiment: Despite the upbeat ratings, forecasts still show the company remaining unprofitable next year (negative EPS), underscoring execution and funding risk for a clinical-stage biotech; this keeps downside risk if pipeline progress or financing plans disappoint. Consensus earnings context

Prime Medicine Company Profile

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.